The Maryland-based biotech firm Novavax announced its latest trial results of its vaccine NVX-CoV2373 against Covid-19, with an efficacy rate of more than 90 per cent even against the variants.
Novavax incidentally is not an mRNA vaccine. The mRNA vaccines, like Pfizer, Moderna and AstraZeneca, contain a piece of genetic code called RNA that the body creates an immune response for. Novavax uses a traditional vaccine approach of using purified pieces of the coronavirus to spur an immune response in the body.
It is reported that the Novavax vaccine also has a substantially lower rate of side effects than the authorized mRNA vaccines. Last week’s data showed that about 40 per cent of people who receive Novavax report fatigue after the second dose, as compared with 65 per cent for Moderna and more than 55 per cent for Pfizer.
Based on the results of Novavax’s first efficacy trial in the U.K., side effects (including but not limited to fatigue) were reported to be less frequent and milder. Results from a Phase 3 clinical trial enrolling 15,000 adults in the United Kingdom showed a two-dose regimen of the vaccine was highly effective in preventing symptomatic COVID-19 overall.
Scientists and Researchers have pointed out that this could create a wide acceptance from the general public, as most of them are apprehensive about the side effects.
Novavax, named Covavax in India, is in the advanced stages of Phase 2/3 trials with the Serum Institute of India (SII), Pune, with 1600 volunteers above 18 years, across various cities in India. It is speculated that SII will introduce the vaccine in India by September 2021.